Pulmonary Pharmacology and Therapeutics Pulmonary Pharmacology and Therapeutics RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations
Publication date: Available online 11 September 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Paola Rogliani, Maria Gabriella Matera, Beatrice Ludovica Ritondo, Ilaria De Guido, Ermanno Puxeddu, Mario Cazzola, Luigino CalzettaAbstractDespite several long-acting β2-adrenoceptors agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved in chronic obstructive pulmonary disease (COPD), there are limited findings concerning the direct comparison across the different LABA/LAMA FDCs. The aim of this study was to compare the efficacy/safety profile of approved LAB...
Source: Pulmonary Pharmacology and Therapeutics - September 11, 2019 Category: Respiratory Medicine Source Type: research

Mycophenolate mofetil as an alternative treatment in sarcoidosis
ConclusionMMF as an alternative drug in systemic sarcoidosis, proved safe and effective, permitting the reduction of the dose of oral CS and leading to clinical, functional and radiological improvement. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 10, 2019 Category: Respiratory Medicine Source Type: research

Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis
ConclusionsWeight loss is common among IPF patients on antifibrotic therapy. Nintedanib therapy and more advanced disease were identified as predictors of weight loss in this population. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 10, 2019 Category: Respiratory Medicine Source Type: research

Quantifying test-retest variability of natural and suppressed citric acid cough thresholds and urge to cough ratings
ConclusionsNatural and suppressed cough thresholds and UTC ratings are subject to test-retest variability. These data are important for the use of citric acid CRT as an outcome measure in longitudinal cough research, as they facilitate interpretation of whether changes in citric acid cough thresholds across days reflect true changes in cough sensitivity, rather than an artefact of repeating the test. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 5, 2019 Category: Respiratory Medicine Source Type: research

Challenges and perspectives in porcine model of acute lung injury using oleic acid
In conclusion, this model shows histological findings of acute lung injury and inflammatory response similar to those of clinical ARDS, it presents high mortality, inconsistent reproducibility and hardly controlled hemodynamic instability. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 4, 2019 Category: Respiratory Medicine Source Type: research

One year of mepolizumab. Efficacy and safety in real-life in Italy
Conclusions & clinical relevanceIn this real-life setting, MEP confirmed its efficacy and safety profile, already shown in clinical trials. This was apparent concerning exacerbation rate, systemic steroids intake and safety. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - August 30, 2019 Category: Respiratory Medicine Source Type: research

ATP cough challenge
Publication date: October 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 58Author(s): Alyn Morice (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - August 20, 2019 Category: Respiratory Medicine Source Type: research

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1)
Publication date: Available online 18 August 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Michael R. Loebinger, Eva Polverino, Francesco Blasi, Stuart J. Elborn, James D. Chalmers, Harm AWM. Tiddens, Herman Goossens, Michael Tunney, Wenchun Zhou, Gerhild Angyalosi, Adam T. Hill, Charles S. Haworth, iBEST-1 Trial TeamAbstractIn patients with bronchiectasis (BE), infection with Pseudomonas aeruginosa (Pa) results in disease progression, frequent pulmonary exacerbations and lung function decline. However, at present, no inhaled antibiotics have been approved for the treatment of these patients. Tobramycin inhal...
Source: Pulmonary Pharmacology and Therapeutics - August 18, 2019 Category: Respiratory Medicine Source Type: research

Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation
Publication date: Available online 1 August 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Di Wang, Xiao-qing Chai, Costan G. Magnnusen, Graeme R. Zosky, Shu-hua Shu, Xin Wei, Shan-shan HuAbstractWhile effective treatments for acute respiratory distress syndrome (ARDS) are lacking, mechanical lung ventilation can sustain adequate gas exchange in critically ill patients with respiratory failure due to ARDS. However, as a result of the phenomenon of ventilator-induced lung injury (VILI), there is an increasing need to seek beneficial pharmacological therapies for ARDS. Recent studies have suggested the renin-ang...
Source: Pulmonary Pharmacology and Therapeutics - August 1, 2019 Category: Respiratory Medicine Source Type: research

Evaluation of patients’ real-world post-dispensing use and storage environments of tiotropium bromide Respimat® soft mist inhaler on its in vitro dose delivery and lung deposition
ConclusionsUsing the R under the fluctuating summer and winter environments of our patients would not affect its overall tiotropium bromide emission performance. The significant increase in the respirable mass of the RS and RW might be offset by the increase in particles <1 μm particularly in patients with poor inhaler technique. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 26, 2019 Category: Respiratory Medicine Source Type: research

Airway delivery of conditioned media from mesenchymal stem cells (MSC-CM) for COPD
Publication date: Available online 24 July 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Avinash Kharat, Vikrant R. Patil, Supriya Kheur, Ramesh Bhonde (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 25, 2019 Category: Respiratory Medicine Source Type: research

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment
Publication date: Available online 23 July 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Maria Gabriella Matera, Barbara Rinaldi, Luigino Calzetta, Paola Rogliani, Mario CazzolaAbstractThe differences in the pharmacokinetic (PK) characteristics of inhaled corticosteroids (ICSs) critically influence the profile of each of them, but also the significant differences in glucocorticoid receptor selectivity, potency, and physicochemical properties are critical in defining the pharmacodynamic (PD) profile of an ICS. The PK and PD properties of ICSs used in asthma and the importance of their interrelationship have be...
Source: Pulmonary Pharmacology and Therapeutics - July 25, 2019 Category: Respiratory Medicine Source Type: research

Effect of doxycyline in chronic obstructive pulmonary disease - An exploratory study
ConclusionThese data suggest that the improvement in lung function and quality of life in COPD patients may probably be attributed to the antioxidant, anti-inflammatory and anti-MMP activity of doxycycline. The potential therapeutic role of long-term doxycycline, in addition to its traditional antibiotic effect, definitely warrants further attention.Graphical abstract (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 25, 2019 Category: Respiratory Medicine Source Type: research

Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose
Publication date: Available online 22 July 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Corrado Pelaia, Maria Teresa Busceti, Alessandro Vatrella, Giuseppe Francesco Rago, Claudia Crimi, Rosa Terracciano, Girolamo PelaiaAbstractBenralizumab is a humanized monoclonal antibody which binds to the α subunit of the interleukin-5 (IL-5) receptor and to the FcγRIIIa receptor expressed by natural killer cells, thus suppressing the pro-eosinophil actions of IL-5 and triggering eosinophil apoptosis via the very effective mechanism of antibody-dependent cell-mediated cytotoxicity (ADCC). Because of its recent approva...
Source: Pulmonary Pharmacology and Therapeutics - July 23, 2019 Category: Respiratory Medicine Source Type: research

A systematic review of methods of citric acid cough reflex testing
ConclusionsConsiderable methodological variability exists for citric acid CRT in published literature. The findings suggest that caution is warranted in comparing citric acid cough thresholds across studies. Full replication of previously published methods of citric acid CRT is limited due to crucial elements of the citric acid CRT protocol being omitted from published manuscripts. These findings have implications on the use of citric acid CRT in clinical and pharmaceutical studies to evaluate the effects of antitussive medications and cough therapies. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 19, 2019 Category: Respiratory Medicine Source Type: research